Associate Research Officer: My research focuses on generating knowledge regarding the interaction between microorganisms and their environment, and then applying this knowledge within the context of ...

Danish drugmaker Novo Nordisk announced Friday that CEO Lars Fruergaard Jørgensen will step down, marking a significant leadership shakeup as the company navigates increasing pressure in the ...

The FDA is prep­ping to rene­go­ti­ate its multi­bil­lion-dol­lar, quin­quen­ni­al user fee agree­ments with the drug in­dus­try lat­er this sum­mer, and a new deputy com­mis­sion ...

Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales and profits forecast and follows a more than 50% decline in the company’s shares since mid-2024.

Lars Fruergaard Jorgensen's departure comes a week after the company downgraded its sales and profits forecast, and follows a more than 50% decline in the company's shares since mid-2024.

Lars Fruergaard Jorgensen, who has headed the Danish pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

The company behind popular new drug Ozempic says its CEO, Lars Fruergaard Jorgensen, will step down following a plunge in the company's share price. Danish pharmaceutical giant Novo Nordisk's ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. Under a mutual ...

As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth ...

As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition ...